Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis
- PMID: 30343317
- PMCID: PMC6697901
- DOI: 10.1007/s00134-018-5328-0
Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis
Abstract
Purpose: A causal biomarker for acute respiratory distress syndrome (ARDS) could fuel precision therapy options. Plasma angiopoietin-2 (ANG2), a vascular permeability marker, is a strong candidate on the basis of experimental and observational evidence. We used genetic causal inference methods-Mendelian randomization and mediation-to infer potential effects of plasma ANG2.
Methods: We genotyped 703 septic subjects, measured ICU admission plasma ANG2, and performed a quantitative trait loci (QTL) analysis to determine variants in the ANGPT2 gene associated with plasma ANG2 (p < 0.005). We then used linear regression and post-estimation analysis to genetically predict plasma ANG2 and tested genetically predicted ANG2 for ARDS association using logistic regression. We estimated the proportion of the genetic effect explained by plasma ANG2 using mediation analysis.
Results: Plasma ANG2 was strongly associated with ARDS (OR 1.59 (95% CI 1.35, 1.88) per log). Five ANGPT2 variants were associated with ANG2 in European ancestry subjects (n = 404). Rs2442608C, the most extreme cis QTL (coefficient 0.22, 95% CI 0.09-0.36, p = 0.001), was associated with higher ARDS risk: adjusted OR 1.38 (95% CI 1.01, 1.87), p = 0.042. No significant QTL were identified in African ancestry subjects. Genetically predicted plasma ANG2 was associated with ARDS risk: adjusted OR 2.25 (95% CI 1.06-4.78), p = 0.035. Plasma ANG2 mediated 34% of the rs2442608C-related ARDS risk.
Conclusions: In septic European ancestry subjects, the strongest ANG2-determining ANGPT2 genetic variant is associated with higher ARDS risk. Plasma ANG2 may be a causal factor in ARDS development. Strategies to reduce plasma ANG2 warrant testing to prevent or treat sepsis-associated ARDS.
Keywords: Angiopoietin-2; Mediation analysis; Mendelian randomization analysis; Respiratory distress syndrome, adult.
Figures
References
-
- Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526–2533 - PubMed
-
- Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH, (2006) Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine 354: 12641272 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 HL140482/HL/NHLBI NIH HHS/United States
- 140026/HL/NHLBI NIH HHS/United States
- R01 HL137006/HL/NHLBI NIH HHS/United States
- K23 HL102254/HL/NHLBI NIH HHS/United States
- R37 HL051856/HL/NHLBI NIH HHS/United States
- HL051856/HL/NHLBI NIH HHS/United States
- HL137006/HL/NHLBI NIH HHS/United States
- R56 HL122474/HL/NHLBI NIH HHS/United States
- HL060710/HL/NHLBI NIH HHS/United States
- R01 HL110969/HL/NHLBI NIH HHS/United States
- HL134356/HL/NHLBI NIH HHS/United States
- HL115354/HL/NHLBI NIH HHS/United States
- RC2 HL101779/HL/NHLBI NIH HHS/United States
- R01 HL060710/HL/NHLBI NIH HHS/United States
- HL125723/HL/NHLBI NIH HHS/United States
- K23 HL125723/HL/NHLBI NIH HHS/United States
- R35 HL140026/HL/NHLBI NIH HHS/United States
- K24 HL115354/HL/NHLBI NIH HHS/United States
- R56 HL134356/HL/NHLBI NIH HHS/United States
- HL122424/HL/NHLBI NIH HHS/United States
- R01 HL051856/HL/NHLBI NIH HHS/United States
- R01 HL122424/HL/NHLBI NIH HHS/United States
- HL101779/HL/NHLBI NIH HHS/United States
- K23 DK097307/DK/NIDDK NIH HHS/United States
- K23 HL116656/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
